Pharma Mar (OTCMKTS:PHMMF) vs. Anebulo Pharmaceuticals (NASDAQ:ANEB) Head-To-Head Comparison

Pharma Mar (OTCMKTS:PHMMF) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, dividends, analyst recommendations and risk.

Risk and Volatility

Pharma Mar has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500. Comparatively, Anebulo Pharmaceuticals has a beta of -1.83, meaning that its stock price is 283% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Pharma Mar and Anebulo Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharma Mar	0	1	1	1	3.00
Anebulo Pharmaceuticals	1	0	0	0	1.00

Earnings & Valuation

This table compares Pharma Mar and Anebulo Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharma Mar	$250.42 million	6.19	$84.84 million	N/A	N/A
Anebulo Pharmaceuticals	N/A	N/A	-$8.48 million	($0.19)	-1.58

Pharma Mar has higher revenue and earnings than Anebulo Pharmaceuticals.

Profitability

This table compares Pharma Mar and Anebulo Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pharma Mar	N/A	N/A	N/A
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%

Institutional and Insider Ownership

28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. 1.9% of Pharma Mar shares are owned by company insiders. Comparatively, 80.6% of Anebulo Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Pharma Mar beats Anebulo Pharmaceuticals on 8 of the 10 factors compared between the two stocks.

About Pharma Mar

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.